Acquisition by Ellis Sean of 7466 shares of Entera Bio subject to Rule 16b-3
| ENTX Stock | USD 2.19 0.14 6.01% |
Slightly above 61% of Entera Bio's investor base is looking to short. The analysis of the overall investor sentiment regarding Entera Bio suggests that many traders are alarmed. Entera Bio's investing sentiment can be driven by a variety of factors including economic data, Entera Bio's earnings reports, geopolitical events, and overall market trends.
Entera |
Filed transaction by Entera Bio Director. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
Entera Bio Fundamental Analysis
We analyze Entera Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Entera Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Entera Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
EBITDA
EBITDA Comparative Analysis
Entera Bio is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Entera Bio Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Entera Bio stock to make a market-neutral strategy. Peer analysis of Entera Bio could also be used in its relative valuation, which is a method of valuing Entera Bio by comparing valuation metrics with similar companies.
Peers
Entera Bio Related Equities
| ATHE | Alterity Therapeutics | 57.04 | ||||
| NLSP | NLS Pharmaceutics | 25.76 | ||||
| IMMP | Immutep | 0.98 |
Additional Tools for Entera Stock Analysis
When running Entera Bio's price analysis, check to measure Entera Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Entera Bio is operating at the current time. Most of Entera Bio's value examination focuses on studying past and present price action to predict the probability of Entera Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Entera Bio's price. Additionally, you may evaluate how the addition of Entera Bio to your portfolios can decrease your overall portfolio volatility.